Apricus Won't Need New Trials To Resubmit ED Cream Vitaros At FDA
Executive Summary
After feedback on a very old complete response, biotech plans to resubmit a filing in the second half of 2017, instead of the fourth quarter, and will need to engage the Office of Product Quality because Vitaros is viewed as a drug/device combination.
You may also be interested in...
Cialis Or Viagra Switch? Sanofi Survey, Pfizer Help Wanted Ad Could Be Signs
Viagra marketer Pfizer also could have nonprescription sales in sight as it recruits a "global sexual health" brand manager with responsibilities including shepherding market expansion through an Rx-to-OTC switch.
Apricus Licenses Its Own Drug Back From Allergan
Apricus Biosciences successfully confused its investors on Sept. 10 when the San Diego-based company announced that it managed to license its own topical treatment for erectile dysfunction (ED) from Allergan for a meager $1m upfront payment plus a future $1.5m regulatory milestone fee.
Nexmed sells US rights to topical ED treatment to Warner Chilcott
Nexmed has agreed to sell the US rights to Vitaros, a topical alprostadil cream for the treatment of erectile dysfunction, to its partnerWarner Chilcott.